Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN – Get Free Report) has received a consensus recommendation of “Moderate Buy” from the twenty-five analysts that are presently covering the firm, Marketbeat.com reports. One equities research analyst has rated the stock with a sell recommendation, six have assigned a hold recommendation, sixteen have given a buy recommendation and two have issued a strong buy recommendation on the company. The average 1 year price objective among analysts that have covered the stock in the last year is $973.13.
REGN has been the topic of several analyst reports. Canaccord Genuity Group lowered shares of Regeneron Pharmaceuticals from a “strong-buy” rating to a “hold” rating in a research report on Tuesday, December 17th. Robert W. Baird dropped their price target on shares of Regeneron Pharmaceuticals from $940.00 to $759.00 and set a “neutral” rating on the stock in a research report on Wednesday, February 5th. Bank of America reaffirmed an “underperform” rating and set a $565.00 price target on shares of Regeneron Pharmaceuticals in a research report on Tuesday, December 10th. Piper Sandler dropped their price target on shares of Regeneron Pharmaceuticals from $1,195.00 to $1,013.00 and set an “overweight” rating on the stock in a research report on Monday, January 27th. Finally, Citigroup dropped their price target on shares of Regeneron Pharmaceuticals from $795.00 to $750.00 and set a “neutral” rating on the stock in a research report on Tuesday, January 28th.
Get Our Latest Analysis on Regeneron Pharmaceuticals
Institutional Inflows and Outflows
Regeneron Pharmaceuticals Stock Performance
Shares of REGN stock opened at $707.51 on Tuesday. The company’s fifty day simple moving average is $696.12 and its 200-day simple moving average is $851.05. The company has a quick ratio of 3.95, a current ratio of 4.73 and a debt-to-equity ratio of 0.09. The firm has a market cap of $77.35 billion, a PE ratio of 18.48, a P/E/G ratio of 2.34 and a beta of 0.27. Regeneron Pharmaceuticals has a 12 month low of $642.00 and a 12 month high of $1,211.20.
Regeneron Pharmaceuticals (NASDAQ:REGN – Get Free Report) last announced its quarterly earnings data on Tuesday, February 4th. The biopharmaceutical company reported $12.07 EPS for the quarter, topping analysts’ consensus estimates of $11.21 by $0.86. The business had revenue of $3.79 billion for the quarter, compared to analyst estimates of $3.76 billion. Regeneron Pharmaceuticals had a net margin of 31.07% and a return on equity of 16.32%. The firm’s revenue for the quarter was up 10.3% on a year-over-year basis. During the same quarter in the previous year, the firm posted $11.86 earnings per share. Equities research analysts expect that Regeneron Pharmaceuticals will post 35.92 EPS for the current fiscal year.
Regeneron Pharmaceuticals Announces Dividend
The firm also recently disclosed a quarterly dividend, which will be paid on Thursday, March 20th. Investors of record on Thursday, February 20th will be issued a $0.88 dividend. The ex-dividend date of this dividend is Thursday, February 20th. This represents a $3.52 dividend on an annualized basis and a yield of 0.50%. Regeneron Pharmaceuticals’s dividend payout ratio (DPR) is presently 2.30%.
Regeneron Pharmaceuticals Company Profile
Regeneron Pharmaceuticals, Inc discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity.
Read More
- Five stocks we like better than Regeneron Pharmaceuticals
- Stock Market Upgrades: What Are They?
- These 4 Tech ETFs Just Hit 50-Day Lows—Time to Buy?
- What Is WallStreetBets and What Stocks Are They Targeting?
- 3 Stocks to Buy While Others Stay on the Sidelines
- How to Short Nasdaq: An Easy-to-Follow Guide
- MarketBeat Week in Review – 03/03 – 03/07
Receive News & Ratings for Regeneron Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Regeneron Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.